18 and older, any sex, with Bradycardia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Chronic CareLink Transmission SuccessPrimary· Scheduled transmissions between 1 and 12 months after enrollment/CareLink activation
To assess CareLink transmission compliance (adherence to scheduled transmission), the primary objective is to compare the percentages of the CareLink quarterly scheduled transmissions that are completed within the prescribed window during the 12-month follow-up after the baseline visit in the CareLink Database between the evaluation patients who use the MyCareLink Heart™ (MCL) app and patients with low power devices and CareLink monitors 2490 (excluding wireless model 2490C). For both patient groups, all scheduled transmissions between 1 and 12 months after enrollment/CareLink activation were
Group
Value
95% CI
Evaluation Group
94.6
91.8 – 96.6
Control Group (Historical)
60.0
59.7 – 60.2
Matched Control Group (Historical)
56.3
53.7 – 58.9
Acute CareLink Transmission SuccessSecondary· Scheduled transmissions in the first month after enrollment
To assess acute CareLink transmission compliance (adherence to scheduled transmission), the secondary objective is to characterize the percentage of the CareLink bi-weekly scheduled transmissions that are completed within the prescribed window during the 1-month follow-up after the baseline visit in the CareLink Database via the MCL Heart™ app. All scheduled transmissions within the first month after enrollment were included in the analysis.
The results reflect the total percentage of completed transmissions pooled across all subjects taking into account that there were several transmissions
Group
Value
95% CI
Evaluation Group
95.1
92 – 97
Sponsor's own description
The purpose of this field evaluation is to collect and evaluate information related to CareLink transmission compliance as well as patient perceived benefit of BlueSync™ and the health care provider perception of the value of BlueSync™ and satisfaction with BlueSync™.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06990243 — Reliability and Validity of the Turkish Version of the SCIPI
· not yet recruiting
Other recruiting trials for Bradycardia
Currently open trials in the same condition.
NCT07209852 — Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
· recruiting
NCT07254013 — Left Bundle Branch Area Pacing (LBBAP) Monitoring Assistant: Evaluation of Portable ECG Solution
· NA
· recruiting
NCT07166614 — Dexmedetomidine vs Propofol in High-Risk ERCP Patients
· NA
· recruiting
NCT07585799 — Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conductio
· NA
· recruiting
NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study
· NA
· recruiting
Other Medtronic Cardiac Rhythm and Heart Failure trials
Trials by the same sponsor.
NCT06910059 — The CT-verified Data Collection Study to Investigate the Correlation Between the Leadless Pacemaker Tip Location and Ech
· active not recruiting
NCT06745778 — Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D
· recruiting
NCT06540521 — Bolt CSP-M Holter Study
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medtronic Cardiac Rhythm and Heart Failure
Last refreshed: 6 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03518658.